Delivery Order SPE2DB20D1110-SPE2DB25FK44H
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) under a firm fixed-price contract valued at $2,392.21. The order carries an ultimate completion date of September 9, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's...
- The Defense Logistics Agency awarded a Delivery Order valued at $5,518.26 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) on September 23, 2025, with completion scheduled for September 24, 2025. This firm fixed-price contract represents a non-competitive delivery order placed under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) with a ceiling value of $6,558.15. This is a firm fixed price delivery order with an ultimate completion date of June 20, 2025, and carries no set-aside designation, indicating it was awarded through competitive procedures. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) with a contract value of $4,557.98. This firm fixed-price delivery order, with an ultimate completion date of July 30, 2025, represents a non-set-aside, competitively awarded procurement supporting federal medical supply needs. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Xifaxan 550 mg tablets in a quantity of 60 units, with a ceiling value of $16,598.12. This firm fixed-price delivery order is part of a competitive procurement with no set-aside designation and is scheduled for completion by September 10, 2025. The place of performance is AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) at a ceiling value of $1,846.22. This firm fixed-price delivery order, which is not set-aside, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The order will be fulfilled from the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Xifaxan 550 mg tablets (60-count) with a ceiling value of $8,948.63. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract. The order is set for ultimate completion by September 11, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Xifaxan 550 mg tablets (60-count packages) under a firm fixed price contract valued at $4,888.67. This competitively awarded delivery order, with no set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,867.95 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) on September 17, 2025, with an ultimate completion date of September 18, 2025. The contract represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a...
- The Defense Logistics Agency awarded a $6,885.33 delivery order to AmerisourceBergen Drug Corp for 60 tablets of Xifaxan 550 mg on September 4, 2025, with an ultimate completion date of September 5, 2025. This competitive award, which utilized firm fixed pricing with no set-aside designation, represents a pharmaceutical delivery under the company's existing contract vehicle with DLA. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- SPE2DB20D1110Indefinite Delivery Contract
- SPE2DB20D1110-SPE2DB25FK44HDelivery Order
The Defense Logistics Agency (DLA) awarded a $12,851.51 delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for the supply of Xifaxan 550 mg tablets (60-count). This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The order is scheduled for completion by September 24, 2025, and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This prime contract vehicle serves as a comprehensive global pharmaceutical support program enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare systems worldwide. AmerisourceBergen's substantial federal contracting portfolio with DLA demonstrates its established capability as a critical pharmaceutical distributor for federal medical procurement, with consistent delivery order awards across multiple therapeutic domains to serve the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.9k | 9/23/25 |